La Jolla Pharmaceutical (NASDAQ:LJPC) reported results from a pre-specified interim analysis of its Phase 2 study of LJPC-401 in patients with hereditary hemochromatosis (HH).
Axovant Gene Therapies (NASDAQ:AXGT) reported six-month data from its Phase 2 trial of AXO-Lenti-PD, a gene therapy for Parkinson’s disease (PD). AXO-Lenti-PD uses a single lentiviral vector to deliver three genes...
ContraVir Pharmaceuticals (NASDAQ:CTRV) reported that CRV431 significantly decreased the extent of fibrosis, or scarring of the liver, in a second animal model of liver fibrosis. CRV431 is a clinical stage cyclophilin...
SVB Leerink downgraded German drug maker InflaRx (NASDAQ:IFRX) to “market perform” from “outperform” and slashed its price target to $4 from $67 after its lead drug failed to benefit patients with a debilitating skin...
Sierra Oncology (NASDAQ:SRRA) received FDA fast track designation for momelotinib for the treatment of myelofibrosis. Momelotinib is designed to improve anemia that frequently occurs in myelofibrosis, or cancer of the...
AnaptysBio (NASDAQ:ANAB) presented updated Phase 2a data of etokimab for the treatment of severe eosinophilic asthma at the European Academy of Allergy and Clinical Immunology congress. Etokimab is a humanized anti...
Concert Pharmaceuticals (NASDAQ:CNCE) completed enrollment in a trial to compare once-daily versus twice-daily dosing of CTP-543 in alopecia areata patients. Alopecia areata is an autoimmune disease that causes partial...
Spectrum Therapeutics, the medical division of Canopy Growth (TSX:WEED; NYSE:CGC) appointed Dr. Marcel Bonn-Miller as global clinical scientific director.
Helius Medical Technologies (NASDAQ:HSDT; TSX:HSM) added three new clinics authorized to provide PoNS treatment in Canada, extending regional access to its innovative treatment.
Aimmune Therapeutics (NASDAQ:AIMT) reported new data from a Phase 3 study of AR101, which delivers a daily dose of peanut protein, as a treatment to reduce the frequency and severity of allergic reactions to peanuts...
ObsEva (NASDAQ:OBSV) completed patient recruitment for its Phase 3 trial of nolasiban for the improvement of rates of pregnancy and live birth in patients undergoing assisted reproduction technology or in-vitro...